Merck Group appoints head of global procurement
Friedheim Felten takes up role on 1 April
Taking up the role on 1 April, Felten succeeds Friedrich Schmitt, who has headed the function since 1997 and will be retiring at the end of July. Felten will report to Michael Becker, chief financial officer.
Corporate procurement is responsible for purchasing production materials such as pharmaceutical raw materials and chemicals, and for procuring technical components such as production and laboratory equipment as well as services such as pharmaceutical research and development. The 500 members of the global matrix organisation handle an annual purchasing volume of around b4.5bn.
Felten joined Merck in July 2009 as head of procurement for Services. He has many years of management experience in purchasing and in other functions at international companies, including DHL Global Forwarding in Singapore, DHL Logistics in London, and BASF AG in Ludwigshafen, as well as various BASF subsidiaries in Asia.
You may also like
Finance
Custom Pharmaceuticals launches new company to foster breakthrough drug development and strategic partnerships
Custom Pharmaceuticals Ltd has launched Centrix Pharma Solutions, a new company dedicated to accelerating drug product development through collaboration with biotech firms and academic research
Finance
Metsera declares $10bn Novo deal "superior" after Pfizer files second lawsuit in GLP-1 row
Metsera has said Novo Nordisk’s revised offer is a “superior proposal” to Pfizer’s, escalating a high-stakes legal and acquisition battle and where Pfizer has filed a second lawsuit accusing Novo of anticompetitive behaviour and Metsera of collusion
Finance
Kimberley-Clark to acquire Tylenol maker Kenvue in landmark $40bn deal
The transaction brings together two iconic American companies to create a combined portfolio of complementary products, including 10 billion-dollar brands, that touch nearly half the global population through every stage of life
Finance
Pfizer sues Metsera and Novo Nordisk over alleged breach of merger agreement
Pfizer has filed a lawsuit against Metsera, its Board of Directors and Novo Nordisk, alleging breach of contract, fiduciary duty and interference following Metsera’s decision to pursue a rival offer that Pfizer claims is “illegal”